Procter & Gamble Co.

PG
NYSEFree primer · Steps 1–3 of 21Coverage as of 2026-Q2
TTM ROIC
17%FY2025
Moat
Wide
Op Margin
24.5%FY2025
Net Debt
$21.0B
Latest Q Revenue
$19.8B+0% YoYQ3 FY2026
Top Holder
Vanguard9.5%
Institutional
72.5%
Bull Case
Sustainable volume recovery and tariff normalization restore premium organic growth, driving meaningful EPS expansion and multiple re-rating.
Bear Case
Structural private-label share gains and persistent tariff headwinds trap organic growth near 1%, compressing margins and P/E multiples.

Business Model


ticker: PG step: 01 generated: 2026-05-11 source: quick-research

The Procter & Gamble Company (PG) — Business Overview

Business Description

Procter & Gamble is the world's largest consumer packaged goods company by revenue, with an iconic portfolio of household and personal-care brands spanning fabric care, home care, baby/feminine/family care, beauty, grooming, and health care. P&G operates on a "superiority" strategy — invest in premium product performance, packaging, brand communication, retail execution, and value — to defend pricing power and capture share against private label.

Revenue Model

  • Fabric & Home Care (~36% of revenue): Detergents, dish, surface care
  • Baby, Feminine & Family Care (~24%): Diapers, period care, paper towels, toilet paper
  • Beauty (~18%): Hair care, skin care, deodorants
  • Health Care (~14%): Oral care, personal health (cold/flu, digestive)
  • Grooming (~8%): Razors, shaving products
  • Mostly mature category growth driven by mix shift to premium tiers + emerging market expansion

Products & Services

  • Fabric & Home Care: Tide, Ariel, Downy, Gain, Cascade, Dawn, Fairy, Febreze, Mr. Clean, Swiffer
  • Baby/Feminine/Family Care: Pampers, Luvs, Always, Tampax, Bounty, Charmin, Puffs
  • Beauty: Pantene, Head & Shoulders, Olay, SK-II, Old Spice, Secret, Native, Herbal Essences
  • Health Care: Crest, Oral-B, Vicks, Metamucil, Pepto-Bismol, Neurobion
  • Grooming: Gillette, Venus, Braun
  • 21+ "billion-dollar brands" generating $1B+ in annual sales each

Customer Base & Go-to-Market

  • Retail customers: Mass retailers (Walmart, Target, Costco, Amazon), drug chains, grocery, club, e-commerce — P&G's top 10 customers are ~40% of sales
  • End consumers: ~5B+ global consumers across 180+ countries
  • B2B: Some hospital and institutional sales (e.g., Tampax to hospitals)
  • Channel mix: Mass + grocery dominant; e-commerce now ~17% of sales and growing

Competitive Position

P&G's primary moats: (1) brand equity built over decades of advertising — many P&G brands have 60%+ category mindshare in their categories; (2) global scale provides advertising, R&D, and supply chain efficiencies private-label and smaller competitors can't match; (3) "superiority" execution discipline keeps premium price tiers defendable; (4) retailer relationships (P&G is often the largest CPG vendor for major retailers). Faces structural pressure from private label (especially in fabric care and family care), the "GLP-1 effect" on snacking-adjacent categories (less direct exposure than Mondelez/Hershey but indirect via reduced retailer foot traffic), and emerging-market FX volatility.

Key Facts

  • Founded: 1837 (William Procter + James Gamble in Cincinnati)
  • Headquarters: Cincinnati, OH
  • Employees: ~108,000
  • Exchange: NYSE
  • Sector / Industry: Consumer Staples / Household Products
  • Market Cap: ~$355B (May 2026)
  • CEO: Jon Moeller (CEO transition announced — Shailesh Jejurikar to succeed in 2026)
  • Dividend: $4.20+ annual; 68+ consecutive years of dividend growth (Dividend King)
  • FY end: June

Financial Snapshot


ticker: PG step: 04 generated: 2026-05-11 source: quick-research

The Procter & Gamble Company (PG) — Financial Snapshot

Note: P&G's fiscal year ends in June. "FY2025" below = fiscal year ended June 30, 2025.

Income Statement Summary

Metric FY2023 FY2024 FY2025 YoY
Net Sales $82.0B $84.0B $84.3B flat
Organic Sales Growth +7% +4% +2% decelerating
Gross Margin 49.0% 51.6% 52.0% +0.4pp
Operating Margin 22.0% 24.0% 24.5% +0.5pp
Net Income $14.7B $14.9B $15.5B +4%
Core EPS (diluted) $5.90 $6.59 $6.85 +4%

Q3 FY2026 Highlights (most recent reported, Jan-Mar 2026)

Metric Q3 FY26 YoY
Net Sales $21.1B +3%
Organic Sales +3% (2% volume, 1% price)
Core EPS $1.59
Adj. FCF Productivity 82%

Segment Performance Q1 FY26 (most relevant)

Segment Organic Growth Volume Notes
Beauty +6% +5% Olay, Pantene drove
Health Care +3% +2% Crest, Oral-B
Grooming +2% flat Pricing-led
Fabric & Home Care +2% +2% Tide volume strong
Baby/Feminine/Family flat +3% (offset by -10% Family Care vol from tariff front-loading)

Cash Flow & Balance Sheet (FY2025)

Metric Value
Cash Flow from Operations $19.8B
Capital Expenditures ~($3.8B)
Free Cash Flow ~$16.0B
FCF Productivity (% of Net Income) 103%
Cash & Investments ~$10B
Total Debt ~$33B

Key Ratios (approximate, May 2026)

  • P/E (forward): ~22x | EV/EBITDA: ~17x | Dividend Yield: ~2.6%
  • ROE: ~30%+ | ROIC: ~17%
  • FCF Yield: ~4.5%
  • Net Debt / EBITDA: ~1.0x

Growth Profile

P&G is in slow-grow territory: FY2025 organic sales +2% (vs. multi-year average ~4-5%), driven by 2% volume and 1% pricing. The pricing fortress (52% gross margin, 24.5% operating margin) remains intact via the "superiority" strategy, but volume in core categories (Family Care -10%) is showing strain from $1B+ tariff costs and consumer trade-down to private label in certain commoditized SKUs. Beauty is the growth bright spot at +6% organic.

Forward Estimates

  • FY2026E Net Sales: ~$87B (+3%)
  • FY2026E Core EPS: ~$6.85-7.10 (consensus, +1-3%)
  • FY2026E FCF: ~$16-17B
  • FY2027E EPS: ~$7.40 (consensus, +5-7%)

Capital Return

  • Dividend $4.20+ annual ($10B+ paid annually) — 68 consecutive years of increases (Dividend King)
  • Share buybacks: $7-9B annual run-rate
  • Total capital return: ~$17-20B annual
  • Long-term target: 60% of earnings as dividend, balance as buybacks

Recent Catalysts


ticker: PG step: 12 generated: 2026-05-11 source: quick-research

The Procter & Gamble Company (PG) — Investment Catalysts & Risks

Bull Case Drivers

  1. Pricing fortress + premiumization defending margins — Despite organic growth decelerating to 2-3%, gross margin expanded to 52% and operating margin to 24.5% in FY25. The "superiority" strategy (premium product / better performance) is allowing P&G to hold price even as private label gains share in some commodity SKUs. New premium launches in 2026 — Pampers AMORE, Swiffer PowerMop upgrades, BEVEL body cream, premium Dawn — extend this playbook.

  2. GLP-1 insulation via hygiene/baby/grooming exposure — Unlike Hershey, Mondelez, Pepsi (where GLP-1 weight-loss drug adoption directly reduces snack consumption), P&G's portfolio is concentrated in daily-use hygiene, baby care, fabric care, and grooming — categories largely independent of dietary changes. P&G is one of the few CPG companies with limited GLP-1 exposure.

  3. Dividend King status (68 consecutive years of increases) — One of only a handful of Dividend Kings, ~$10B annual dividend at 60%+ payout ratio. Combined with ~$8B buybacks, P&G returns ~$18-20B annually = ~5% combined yield. The dividend track record gives PG a "bond-like" institutional bid even in a low-growth environment.

  4. Beauty acceleration (Q1 FY26 +6% organic) — Olay, Pantene, Head & Shoulders, SK-II, Native are driving outsized growth in skin and hair care. Premium beauty has stronger pricing power than commoditized fabric/family care; if Beauty continues at 6%+, it can lift blended growth toward 4%+ over time.

Bear Case Risks

  1. $1B+ tariff headwind + Family Care volume drop — New 2026 tariffs added ~$1B to cost base. Family Care volume dropped 10% YoY in Q1 FY26, attributed to consumers front-loading purchases in late 2025 to beat the January 1 tariff schedule. If tariffs persist and PG can't fully price through, margin compresses materially.

  2. Private label encroachment — In fabric care and family care specifically, retailer-brand competitors (Costco's Kirkland, Walmart's Great Value, Amazon Basics) have improved quality and won shelf space. P&G volume in commoditized SKUs (Bounty, Charmin in some channels) faces structural pressure even at premium price tiers.

  3. Slow organic growth (~2-3%) at premium multiple — Stock trades at ~22x forward EPS with FY26 EPS growth of only +1-3%. PEG ~5x+. If the U.S. consumer downshifts further or emerging-market FX weakens, missing already-low estimates could trigger meaningful multiple compression on a "Dividend King premium" that bears argue is unjustified.

  4. CEO transition risk — Jon Moeller stepping down; Shailesh Jejurikar (current COO, longtime P&G insider) taking over in 2026. Even with internal succession, a multi-year strategic refresh under new leadership can introduce execution risk during sluggish growth.

Upcoming Events

  • Q4 FY26 earnings (July 2026) — Tariff impact full quarterly run-rate; FY27 organic growth/EPS guidance
  • Jejurikar formal CEO start — TBD 2026 — first capital allocation/strategy update
  • Annual Investor Day 2026 — Long-term algorithm, premium portfolio review
  • Cost productivity programs — Multi-year $1.5B savings initiatives offsetting tariffs
  • Q1 FY27 earnings (October 2026) — First full quarter under new CEO; back-to-school + flu-season volume signal

Analyst Sentiment

Sell-side consensus is Hold / Buy with average price targets in the $165-175 range vs. recent ~$152 trading levels. Bulls cite the pricing fortress, GLP-1 insulation, and 68-year dividend track record. Bears focus on the premium 22x multiple, organic growth deceleration, tariff cost pressure, and private label encroachment in commoditized categories.

Research Date

Generated: 2026-05-11

Full Research Available

This primer covers steps 1–3 of 21. The full deep dive includes moat analysis, DCF valuation, bull/bear scenarios, management quality, earnings transcript analysis, competitive positioning, returns on capital, institutional/insider activity, and an investment memo.

View Investment MemoEach memo is $2. Coverage subscriptions for funds coming soon — join the waitlist.